LATITUDE: Phase III Trial of Androgen Deprivation Therapy with Abiraterone for Prostate Cancer

LATITUDE: Phase III Trial of Androgen Deprivation Therapy with Abiraterone for Prostate Cancer

User Photo
AnnualMeeting2017

3 years
337 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the LATITUDE trial, a phase III trial on androgen deprivation therapy (ADT) with abiraterone in newly diagnosed, high-risk, metastatic prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Up Next Autoplay